The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials

Arthritis and Rheumatism

Volumn 54, Issue 2, 2006, Pages 421-432

  Liang, Matthew H ^a,b   Schur, Peter H ^a   Fortin, Paul ^a   St Clair, E William ^a   Balow, James E ^a   Costenbader, Karen ^a   Crofford, Leslie ^a   De Pablo, Paola ^c   Dooley, Mary Anne ^c   Finckh, Axel ^c   Gordon, Caroline P ^c   Lundberg, Ingrid E ^c   Meyrier, Alain ^c   Nived, Ola ^c   Ponticelli, Claudio ^c   Schneider, Matthias K ^c   Singh, Ajay ^c   Wallace, Daniel J ^c  

^a American College of Rheumatology Committee on Research Liaison   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL SOCIETY; MEMBRANOUS GLOMERULONEPHRITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN URINE LEVEL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; URINE SEDIMENT;

AMERICAS; CLINICAL TRIALS; ENDPOINT DETERMINATION; HUMANS; LUPUS NEPHRITIS; MEDLINE; RHEUMATOLOGY; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 32444443319     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21625     Document Type: Review

References (126)

1. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004;50:3418-26.
2. Ad Hoc Working Group on Steroid-Sparing Criteria in Lupus. Criteria for steroid-sparing ability of interventions in systemic lupus erythematosus: report of a consensus meeting. Arthritis Rheum 2004;50:3427-31.
3. Boumpas DT, Balow JE. Outcome criteria for lupus nephritis trials: a critical overview. Lupus 1998;7:622-9.
4. Westgard JO, Groth T, Aronsson T, Falk H, de Verdier CH. Performance characteristics of rules for internal quality control: probabilities for false rejection and error detection. Clin Chem 1977;23:1857-67.
5. Centers for Disease Control and Prevention. Clinical Laboratory Improvement Amendments (CLIA). URL: http://www.phppo. cdc.gov/clia.
6. Churg J, Sobin LH. Renal disease: classification and atlas of glomerular diseases. Tokyo: Igaku-Shoin; 1982.
7. MacGowan JR, Ellis S, Griffiths M, Isenberg DA. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford) 2002;41:981-7.
8. Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: a study of 87 patients and review of the literature. Q J Med 1989;72:779-833.
9. Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002;46:995-1002.
10. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus [published erratum appears in Lancet 1995;346:516]. Lancet 1995;345:1595-9.
11. Derksen RH, Hene RJ, Kallenberg CG, Valentijn RM, Kater L. Prospective multicentre trial on the short-term effects of plasma exchange versus cytotoxic drugs in steroid-resistant lupus nephritis. Neth J Med 1988;33:168-77.
12. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544-50.
13. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995;10:1620-8.
14. Laitman RS, Glicklich D, Sablay LB, Grayzel AI, Barland P, Bank N. Effect of long-term normalization of serum complement levels on the course of lupus nephritis. Am J Med 1989;87:132-8.
15. Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002;17:72-7.
16. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD, and the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000;35:904-14.
17. Levey AS, Lan SP, Corwin HL, Kasinath BS, Lachin J, Neilson EG, et al. Progression and remission of renal disease in the Lupus Nephritis Collaborative Study: results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med 1992;116:114-23.
18. Martins L, Rocha G, Rodrigues A, Santos J, Vasconcelos C, Correia J, et al. Lupus nephritis: a retrospective review of 78 cases from a single center. Clin Nephrol 2002;57:114-9.
19. Mackay IR, Robson G, Chan D. Prednisolone treatment of lupus nephritis: effect of high doses on course of disease, renal function, histological lesions, and immunological reactions. Australas Ann Med 1970;19:123-30.
20. Bakir AA, Levy PS, Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am J Kidney Dis 1994;24:159-71.
21. Dooley MA, Hogan S, Jennette C, Falk R, and the Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997;51:1188-95.
22. Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JH, Swaak TJ. Contribution of renal biopsy data in predicting outcome in lupus nephritis: analysis of 116 patients. Arthritis Rheum 1990;33:970-7.
23. McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 1994;37:559-67.
24. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987;83:877-85.
25. Austin HA III, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
26. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354:569-70.
27. Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
28. Decker JL, Klippel JH, Plotz PH, Steinberg AD. Cyclophosphamide or azathioprine in lupus glomerulonephritis: a controlled trial: results at 28 months. Ann Intern Med 1975;83:606-15.
29. Austin HA III, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983;75:382-91.
30. Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine (Baltimore) 1999;78:148-66.
31. Donadio JV Jr, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995;4:109-15.
32. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002;46:1003-13.
33. Donadio JV Jr, Holley KE, Wagoner RD, Ferguson RH, McDuffie FC. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 1972;77:829-35.
34. Sloan RP, Schwartz MM, Korbet SM, Borok RZ, and the Lupus Nephritis Collaborative Study Group. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 1996;7:299-305.
35. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996;50:2047-53.
36. Shayakul C, Ong-aj-yooth L, Chirawong P, Nimmannit S, Parichatikanond P, Laohapand T, et al. Lupus nephritis in Thailand: clinicopathologic findings and outcome in 569 patients. Am J Kidney Dis 1995;26:300-7.
37. Lim CS, Chin HJ, Jung YC, Kim YS, Ahn C, Han JS, et al. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol 1999;52:139-47.
38. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000;57:258-64.
39. McCluskey RT. Lupus nephritis. In: Sommers SC, editor. Pathology decennial 1966-1975. New York: Appleton Century Crofts; 1975. p. 435-60.
40. Gruppo Italiano per lo Studio della Nefrite Lupica. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992;19:473-9.
41. Naiker IP, Chrystal V, Randeree IG, Seedat YK. The significance of arterial hypertension at the onset of clinical lupus nephritis. Postgrad Med J 1997;73:230-3.
42. Neumann K, Wallace DJ, Azen C, Nessim S, Fichman M, Metzger AL, et al. Lupus in the 1980s. III. Influence of clinical variables, biopsy, and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995;25:47-55.
43. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking. Arch Intern Med 1992;152:2082-8.
44. Goulet JR, MacKenzie T, Levinton C, Hayslett JP, Ciampi A, Esdaile JM. The longterm prognosis of lupus nephritis: the impact of disease activity. J Rheumatol 1993;20:59-65.
45. Soffer LJ, Southren AL, Weiner HE, Wolf RL. Renal manifestations of systemic lupus erythematosus: a clinical and pathologic study of 90 cases. Ann Intern Med 1961;54:215-28.
46. Baldwin DS, Gluck MC, Lowenstein J, Gallo GR. Lupus nephritis: clinical course as related to morphologic forms and their transitions. Am J Med 1977;62:12-30.
47. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64.
48. Balow JE, Austin HA III, Muenz LR, Joyce KM, Antonovych TT, Klippel JH, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984;311:491-5.
49. Arce-Salinas CA, Villa AR, Martinez-Rueda JO, Munoz L, Cardiel MH, Alcocer-Varela J, et al. Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study. Lupus 1995;4:197-203.
50. Donadio JV Jr, Glassock RJ. Immunosuppressive drug therapy in lupus nephritis. Am J Kidney Dis 1993;21:239-50.
51. Blanco FJ, de la Mata J, Lopez-Fernandez JI, Gomez-Reino JJ. Light, immunofluorescence and electron microscopy renal biopsy findings as predictors of mortality in eighty-five Spanish patients with systemic lupus erythematosus. Br J Rheumatol 1994;33:260-6.
52. Moroni G, Pasquali S, Quaglini S, Banfi G, Casanova S, Maccario M, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis 1999;34:530-9.
53. Ferluga D, Jerse M, Vizjak A, Hvala A, Rozman B, Kos-Golja M, et al. Correlation among WHO classes, histomorphologic patterns of glomerulonephritis and glomerular immune deposits in SLE. Wien Klin Wochenschr 2000;112:692-701.
54. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001;59:2156-63.
55. Park MH, D'Agati V, Appel GB, Pirani CL. Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 1986;44:309-19.
56. Leaker B, Fairley KF, Dowling J, Kincaid-Smith P. Lupus nephritis: clinical and pathological correlation. Q J Med 1987;62:163-79.
57. Valeri A, Radhakrishnan J, Estes D, D'Agati V, Kopelman R, Pernis A, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol 1994;42:71-8.
58. Fraenkel L, MacKenzie T, Joseph L, Kashgarian M, Hayslett JP, Esdaile JM. Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol 1994;21:2052-7.
59. Falk RJ. Treatment of lupus nephritis: a work in progress. N Engl J Med 2000;343:1182-3.
60. Esdaile JM. Current role of renal biopsy in patients with SLE. Baillieres Clin Rheumatol 1998;12:433-48.
61. Golbus J, McCune WJ. Lupus nephritis: classification, prognosis, immunopathogenesis, and treatment. Rheum Dis Clin North Am 1994;20:213-42.
62. Austin HA, Balow JE. Natural history and treatment of lupus nephritis. Semin Nephrol 1999;19:2-11.
63. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24.
64. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-8.
65. Godfrey T, Cuadrado MJ, Fofi C, Abbs I, Khamashta MA, Nunan T, et al. Chromium-51 ethylenediamine tetraacetic acid glomerular filtration rate: a better predictor than glomerular filtration rate calculated by the Cockcroft-Gault formula for renal involvement in systemic lupus erythematosus patients. Rheumatology (Oxford) 2001;40:324-8.
66. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin Arthritis Rheum 1993;23:135-48.
67. Levey AS. Measurement of renal function in chronic renal disease. Kidney Int 1990;38:167-84.
68. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steifes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [published erratum appears in Ann Intern Med 2003;139:605]. Ann Intern Med 2003;139:137-47.
69. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39 (2 Suppl 1):S1-266.
70. Patel SS, Kimmel PL, Singh A. New clinical practice guidelines for chronic kidney disease: a framework for K/DOQI. Semin Nephrol 2002;22:449-58.
71. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
72. Wang F, Looi LM. Systemic lupus erythematosus with membranous lupus nephropathy in Malaysian patients. Q J Med 1984;53:209-26.
73. Wallace DJ, Podell TE, Weiner JM, Cox MB, Klinenberg JR, Forouzesh S, et al. Lupus nephritis: experience with 230 patients in a private practice from 1950 to 1980. Am J Med 1982;72:209-20.
74. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med 1971;75:165-71.
75. Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum 1974;17:923-37.
76. Nossent JC, Bronsveld W, Swaak AJ. Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 1989;48:810-6.
77. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982;96:728-36.
78. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med 1975;83:597-605.
79. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978;299:1151-5.
80. Steinberg AD, Gourley M. Cyclophosphamide in lupus nephritis. J Rheumatol 1995;22:1812-5.
81. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001;28:2103-8.
82. Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol 2004;31:1557-9.
83. Rasoulpour M, Banco L, Laut JM, Burke GS. Inability of community-based laboratories to identify pathological casts in urine samples. Arch Pediatr Adolesc Med 1996;150:1201-4.
84. Hebert LA, Dillon JJ, Middendorf DF, Lewis EJ, Peter JB. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995;26:432-8.
85. Cameron JS, Boulton-Jones M, Robinson R, Ogg C. Treatment of lupus nephritis with cyclophosphamide. Lancet 1970;2:846-9.
86. Lewis EJ. The treatment of lupus nephritis: revisiting Galen. Ann Intern Med 2000;135:296-8.
87. Gourley MF, Austin HA III, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996;125:549-57.
88. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM, and the Lupus Nephritis Collaborative Study Group. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992;326:1373-9.
89. Moroni G, Banfi G, Ponticelli C. Clinical status of patients after 10 years of lupus nephritis. Q J Med 1992;84:681-9.
90. Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999;8:545-51.
91. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, and the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343:1156-62.
92. Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998;31:681-6.
93. Pasquali S, Banfi G, Zucchelli A, Moroni G, Ponticelli C, Zucchelli P. Lupus membranous nephropathy: long-term outcome. Clin Nephrol 1993;39:175-82.
94. Austin HA. Clinical evaluation and monitoring of lupus kidney disease. Lupus 1998;7:618-21.
95. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature. Lupus 2000;9:241-51.
96. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
97. Berden JH. Lupus nephritis. Kidney Int 1997;52:538-58.
98. Martinelli R, Pereira LJ, Santos ES, Rocha H. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus. Nephron 1996;74:313-7.
99. Conlon PJ, Fischer CA, Levesque MC, Smith SR, St.Clair EW, Allen NB, et al. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996;46:170-5.
100. Donadio JV Jr, Burgess JH, Holley KE. Membranous lupus nephropathy: a clinicopathologic study. Medicine (Baltimore) 1977;56:527-36.
101. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
102. European urinalysis guidelines. Scand J Clin Lab Invest Suppl 2000;231:1-86.
103. Cancer Therapy Evaluation Programs: Common Toxicity Criteria Version 2.0. Bethesda (MD): National Institutes of Health, National Cancer Institute; 1990.
104. Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, et al. Standardizing assessment of adverse effects in rheumatology clinical trials: status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001;28:1163-9.
105. National Cancer Institute. Common terminology criteria for adverse events. Version 3.0. Rockville (MD): Cancer Therapy Evaluation Program, NCI, NIH, Department of Health and Human Services; December 15, 2004. URL: http://ctep.cancer. gov/reporting/newadverse_2005.pdf.
106. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited [published erratum appears in J Am Soc Nephrol 2004;15:835-6]. J Am Soc Nephrol 2004;15:241-50.
107. Pollak VE, Pirani CL, Schwartz FD. The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med 1964;63:537-50.
108. Pollak VE, Kant KS, Hariharan S. Diffuse and focal proliferative lupus nephritis: treatment approaches and results. Nephron 1991:59:177-93.
109. Pollak VE, Pirani CL, Kark RM. Effect of large doses of prednisone on the renal lesions and life span of patients with lupus glomerulonephritis. J Lab Clin Med 1961;57:495-511.
110. Grande JP, Balow JE. Renal biopsy in lupus nephritis. Lupus 1998:7:611-7.
111. Donadio JV Jr, Holley KE, Wagoner RD, Ferguson RH, McDuffie FC. Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Arthritis Rheum 1974;17:573-81.
112. Lewis EJ. The natural history and treatment of lupus nephritis. In: Lewis MM, Korbet SM, editors. Lupus nephritis. Oxford: Oxford University Press; 1999. p. 185-218.
113. Wernick RM, Smith DL, Houghton DC, Phillips DS, Booth JL, Runckel DN, et al. Reliability of histologicscoring for lupus nephritis: a community-based evaluation. Ann Intern Med 1993;119:805-11.
114. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ, and the Lupus Nephritis Collaborative Study Group. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Am J Kidney Dis 1993;21:374-7.
115. Mahajan SK, Ordonez NG, Feitelson PJ, Lim VS, Spargo BH, Katz AI. Lupus nephropathy without clinical renal involvement. Medicine (Baltimore) 1977;56:493-501.
116. Leehey DJ, Katz AI, Azaran AH, Aronson AJ, Spargo BH. Silent diffuse lupus nephritis: long-term follow-up. Am J Kidney Dis 1982;2:188-96.
117. Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289:2554-9.
118. Ginzler E, Diamond H, Guttadauria M, Kaplan D. Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum 1976;19:693-9.
119. Barron KS, Person DA, Brewer EJ Jr, Beale MG, Robson AM. Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis. J Pediatr 1982;101:137-41.
120. Carette S, Klippel JH, Decker JL, Austin HA, Plotz PH, Steinberg AD, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis: a long-term follow-up. Ann Intern Med 1983;99:1-8.
121. Clark WF, Cattran DC, Balfe JW, Williams W, Lindsay RM, Linton AL. Chronic plasma exchange in systemic lupus erythematosus nephritis. Proc Eur Dial Transplant Assoc 1983;20:629-35.
122. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
123. Witte T, Schaumann D, Hein R, Neumann KH, Koch KM, Deicher H, et al. [Cyclophosphamide bolus therapy in lupus nephritis-status of the clinical study]. Immun Infekt 1993;21 Suppl 1:24-6. In German.
124. Doria A, Piccoli A, Vesco P, Vaccaro E, Marson P, De Silvestro G, et al. Therapy of lupus nephritis: a two-year prospective study. Ann Med Interne (Paris) 1994;145:307-11.
125. Wallace DJ, Goldfinger D, Pepkowitz SH, Fichman M, Metzger AL, Schroeder JO, et al. Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J Clin Apher 1998;13:163-6.
126. Nakamura T, Ushiyama C, Hara M, Osada S, Ugai K, Shimada N, et al. Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis. Clin Nephrol 2002;57:108-13.